Ensign Peak Advisors, Inc Atara Biotherapeutics, Inc. Transaction History

Ensign Peak Advisors, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $484,890 - $1.49 Million	-170,137 Reduced 74.78%	57,390 $217,000
Q2 2022 Aug 12, 2022	BUY	$4.69 - $9.84 $299,972 - $629,366	63,960 Added 39.1%	227,527 $1.77 Million
Q1 2022 May 16, 2022	BUY	$8.44 - $16.89 $1.23 Million - $2.46 Million	145,647 Added 812.76%	163,567 $1.52 Million
Q4 2021 Feb 11, 2022	SELL	$14.7 - $19.89 $746,760 - $1.01 Million	-50,800 Reduced 73.92%	17,920 $282,000
Q3 2021 Nov 12, 2021	BUY	$11.99 - $17.9 $823,952 - $1.23 Million	68,720 New	68,720 $1.23 Million

Q1 2021 May 12, 2021	SELL	$14.0 - $20.72 $698,572 - $1.03 Million	-49,898 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$11.92 - $15.87 $594,784 - $791,881	49,898 New	49,898 $647,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.